Pfizer (NYSE:PFE) today announced that it has entered into an agreement to acquire Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), which is best known for Nurtec ODT (rimegepant), a dual-acting migraine therapy. Pfizer will pay $148.50 per share in cash to acquire Biohaven, totaling approximately $11.6 billion. Get the full story from our sister site, Pharmaceutical […]
